Trial · NCT01336972
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Final treatment change from Baseline | -8.0 | Standard Deviation 9.1 | mL/min |
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Final treatment change from Baseline | -6.2 | Standard Deviation 6.2 | mL/min |
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Final treatment change from Baseline | -0.7 | Standard Deviation 1.5 | mL/min |
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Post treatment change from Baseline | 0.1 | Standard Deviation 4.9 | mL/min |
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Post treatment change from Baseline | -1.5 | Standard Deviation 4.0 | mL/min |
| Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Post treatment change from Baseline | -1.2 | Standard Deviation 3.0 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Final treatment change from Baseline | -16.9 | Standard Deviation 36.4 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Final treatment change from Baseline | -11.1 | Standard Deviation 18.4 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Final treatment change from Baseline | -1.7 | Standard Deviation 5.1 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Post treatment change from Baseline | 4.3 | Standard Deviation 30.2 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Post treatment change from Baseline | -8.4 | Standard Deviation 17.7 | mL/min |
| Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Post treatment change from Baseline | -1.3 | Standard Deviation 10.3 | mL/min |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Final treatment change from Baseline | -0.005 | Standard Deviation 0.017 | Ratios |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Final treatment change from Baseline | -0.013 | Standard Deviation 0.016 | Ratios |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Final treatment change from Baseline | -0.010 | Standard Deviation 0.014 | Ratios |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR > 60 mL/Min/1.73m2 | Post treatment change from Baseline | -0.003 | Standard Deviation 0.018 | Ratios |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR 30-60 mL/Min/1.73m2 | Post treatment change from Baseline | 0.005 | Standard Deviation 0.015 | Ratios |
| Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment. | eGFR <30 mL/Min/1.73m2 | Post treatment change from Baseline | -0.016 | Standard Deviation 0.023 | Ratios |
| Mean Change From Baseline in Free Water Clearance After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment | eGFR > 60 mL/Min/1.73m2 | Final treatment change from Baseline | 4.334 | Standard Deviation 3.268 | mL/min |
| Mean Change From Baseline in Free Water Clearance After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment | eGFR 30-60 mL/Min/1.73m2 | Final treatment change from Baseline | 2.822 | Standard Deviation 1.715 | mL/min |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01336972/results